Gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer abutting on gastrointestinal tract

Gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer abutting on gastrointestinal tract - Gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer abutting on gastrointestinal tract

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008785

Enrollment

Registered

2012-08-28

Start date

2012-08-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

proton radiotherapy Chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: locally advanced pancreatic cancer abutting on gastrointestinal tract

Exclusion criteria

Exclusion criteria: distant metastasis

Design outcomes

Primary

Measure	Time frame
late gastrointestinal toxicity early toxicity	—

Secondary

Measure	Time frame
local efficacy local control rate survival time	—

Countries

Japan

Contacts

Public ContactKazuki Terashima

Hyogo Ion Beam Medical Center Department of Radiology

k.terashima@hibmc.shingu.hyogo.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026